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Patients without serum anti-cMV 
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The absence of anti-cytomegalovirus (CMV) immunoglobulin G (IgG) is used to classify 
pretransplant patients as naïve for CMV infection (CMVneg patients). This study assessed 
whether pretransplant CMV-specific T-cell immunity exists in CMVneg patients and 
whether it protects against CMV infection after kidney transplantation. The results show 
that CMV-specific CD137+IFNγ+CD4+ and CD137+IFNγ+CD8+ memory T  cells were 
present in 46 and 39% of CMVneg patients (n = 28) although at much lower frequencies 
compared to CMVpos patients (median 0.01 versus 0.58% for CD4+ and 0.05 versus 
0.64% for CD8+ T cells) with a less differentiated CD28-expressing phenotype. In line with 
these data, CMV-specific proliferative CD4+ and CD8+ T cells were observed in CMVneg 
patients, which significantly correlated with the frequency of CMV-specific T cells. CMV-
specific IgG antibody-secreting cells (ASC) could be detected at low frequency in 36% 
of CMVneg patients (1 versus 45 ASC/105 cells in CMVpos patients). CMVneg patients with 
pretransplant CMV-specific CD137+IFNγ+CD4+ T cells had a lower risk to develop CMV 
viremia after transplantation with a CMVpos donor kidney (relative risk: 0.43, P = 0.03). 
In conclusion, a solitary CMV-specific T-cell response without detectable anti-CMV 
antibodies is frequent and clinically relevant as it is associated with protection to CMV 
infection following transplantation with a kidney from a CMVpos donor.
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inTrODUcTiOn
Kidney transplant (KT) recipients are at increased risk for infections following transplantation, 
one of the major threats being cytomegalovirus (CMV). A primary infection or reactivation with 
CMV may cause a viremia and can lead to severe CMV disease with organ involvement (1). Patients 
at increased risk for an infection with CMV either receive prophylactic or preemptive antiviral 
therapy (valganciclovir) following kidney transplantation (2). Classification of the risk for a CMV 
infection before KT is based on the presence of anti-CMV immunoglobulin G (IgG) in the patient 
in combination with the CMV serostatus of the kidney donor. Immunity to viruses, for example, 
CMV, is dependent on adequate help from CMV-specific CD4+ T  cells enabling production of 
TaBle 1 | Demographic and clinical characteristics of study population.
D+/r+ 
(n = 14)
D+/
r− (n = 28)
P-
value
Age in yearsa,b 50 (19–63) 47.5 (21–76) NS
Male 50% (7) 68% (19) NS
Cytomegalovirus (CMV) immunoglobulin  
G titer (AU/mL)
47.5 (9–354)
CMV viremia 0% 46% (13) <0.01
Time point of CMV viremia post-kidney 
transplant (KT) (months)
5 (2–12)
Renal replacement therapyb NS
 – Preemptive transplantation
 – Patients on dialysis
43% (6) 43% (12)
57% (8) 57% (16)
Underlying kidney diseaseb NS
 – Nephrosclerosis/atherosclerosis/
hypertension
 – Primary glomerulopathies
 – Diabetes
 – Urinary tract infections/stones
 – Reflux nephropathy
 – Polycystic kidney disease
 – Other/unknown
14% (2) 25% (7)
36% (5) 29% (8)
21% (3) 11% (3)
3% (1)
3% (1)
7% (2)
29% (4) 22% (6)
Previous KTb 1 1 NS
Mismatches HLA class Ia 2 (1–4) 2 (0–4) NS
Mismatches HLA class IIa 1 (0–2) 1 (0–2) NS
Immunosuppressive medication
 – Basiliximab induction therapyc
 – Prednisoloned
 – MMF
 – Tacrolimus
 – Switch tacrolimus → everolimuse
79% (11)
100% (14)
100% (14)
93% (13)
7% (1)
89% (25)
100% (28)
100% (28)
93% (26)
7% (2)
NS
NS
NS
NS
NS
Donor age in yearsa,b 42 (27–66) 57 (29–72) <0.01
aMedian (min–max).
bAt pre-KT.
cGiven at day 0 and day 4 post-KT.
dGiven the first 3 months post-KT.
e6 months post-KT.
NS, not significant.
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neutralizing antibodies by CMV-specific B-cells/plasma blasts 
and effective cytotoxic CD8+ T  cell (CTL) responses (3–5). 
Absence of neutralizing antibodies does not necessarily imply 
that the antigen was not encountered before as cellular immunity 
might still be present. Furthermore, it is known that in end-stage 
renal disease (ESRD) patients protective humoral immunity is 
not maintained and often not achieved (6, 7). Therefore, several 
groups have proposed to include an evaluation of cellular immu-
nity against CMV in the risk assessment strategy to more accu-
rately assess sensitization before transplantation (8–10). Data are 
scarce as to whether the presence of limited cellular immunity 
protects from CMV viremia after kidney transplantation and no 
detailed insights into which T-cell subsets are involved in just-
sufficient protection are available, as cellular immunity is mainly 
assessed by ELISpot (11).
T-cell differentiation can be assessed by using expression of 
CD45RO or CD45RA and the lymph node homing chemokine 
receptor CCR7 which is able to identify naive T cells and differ-
ent memory T cell subsets, i.e., central memory (CM), effector 
memory (EM), and finally terminally differentiated EM CD45RA+ 
(EMRA) (12). This is accompanied by loss of the co-stimulatory 
marker CD28. Particularly, an effective CMV-specific T cell res-
ponse yields many highly differentiated CD28null T cells (13, 14). 
As we have previously shown, this T-cell response adds to immu-
nological T-cell aging observed in the circulation of ESRD 
patients, resulting in a shift toward more differentiated memory 
T cells and enhanced telomere attrition (14, 15). Whether pres-
ence of limited cellular immunity to CMV impacts T-cell aging 
characteristics in ESRD patients is not known.
The aim of this study is to assess CMV-specific T-cell immu-
nity including the differentiation stage of CMV-specific T cells 
and to determine its clinical relevance with respect to protection 
from CMV viremia following transplantation in a cohort of 
CMV-seronegative patients. Furthermore, the impact on T-cell 
aging parameters was evaluated.
MaTerials anD MeThODs
study Population
In a cohort of stable CMV-seronegative and, as a control, age- and 
gender-matched CMV-seropositive recipients of a kidney from 
a CMV-seropositive donor (D+/R− and D+/R+, respectively), 
CMV-specific immunity was assessed before transplantation 
and linked to CMV viremia following KT. Most of the patients 
(86%) received induction therapy with basiliximab (Simulect®, 
Novartis). The standard triple immunosuppression given follow-
ing transplantation consisted of tacrolimus (Prograf®, Astellas 
Pharma), mycophenolate mofetil (Cellcept®, Roche), and 
prednisolone (the first 3 months post-KT), the first given to 93% 
and the latter two to all of the patients. The first 6 months fol-
lowing transplantation, antiviral prophylaxis with valganciclovir 
450 mg q.d. was given and if necessary adjusted for impairment 
of renal function. Patient characteristics are listed in Table  1. 
All patients gave written informed consent to participate in this 
study. The study was approved by the Medical Ethical Committee 
of the Erasmus MC (METC number 2010-080) and conducted in 
accordance with the Declaration of Helsinki and the Declaration 
of Istanbul.
Detection of cMV Viremia and  
cMV-specific antibodies
Serum IgG antibodies to CMV [expressed as arbitrary units/
mL (AU/mL)] were measured with an enzyme immune assay 
(Biomerieux, VIDAS, Lyon, France). An outcome of ≥6 AU/mL 
was considered positive. Patients were monitored at a 3 months 
interval during the first year following transplantation with 
respect to presence of CMV DNA. Diagnosis of a CMV-viremic 
episode was based on the presence of copies [expressed in 
international units/mL (IU/mL)] of CMV DNA in blood and 
established by a quantitative polymerase chain reaction at the 
department of Virology at the Erasmus MC. An outcome of 
>50 IU/mL was indicative for a CMV viremia.
isolation of Peripheral Mononuclear  
cells (PBMcs)
Before KT, PBMCs were isolated as described in detail before (16) 
from heparinized blood samples drawn from CMV-seronegative 
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and CMV-seropositive patients and stored at 10 million PBMCs 
per vial at −150°C until further use.
Detection of cMV-specific cD137-
expressing cytokine-Producing T cells
Peripheral mononuclear cells of 28 CMV-seronegative and 14 
CMV-seropositive patients were thawed, allowed to rest for 8 h at 
37°C and stimulated (5 × 106 PBMCs/mL) in RPMI-1640 contain-
ing glutamax (GibcoBRL, Paisley, Scotland) supplemented with 
100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% heat-
inactivated pooled human serum, further referred to as standard 
culture medium. Stimulation was performed in polystyrene tubes 
(BD Pharmingen, Erembodegem, Belgium) in the presence of co-
stimulation CD49d (1 µg/mL; BD) without (background) or with 
a mixture of overlapping peptide pools covering the whole pp65 
and IE-1 protein of CMV (1 µg/mL; PepTivator-CMV pp65 and 
IE-1; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and 
brefeldin A (Golgiplug; BD Pharmingen) for 12 h. This intracel-
lular cytokine staining assay facilitates detailed characterization 
of CMV-specific CD4+ as well as CD8+ T cells as these can be 
identified by de novo expression of CD137 in combination with 
effector molecules (17). As a positive control, PBMC of 10 CMV-
seronegative and 5 CMV-seropositive patients was stimulated with 
the combination of phorbol myristate acetate (PMA; 50 ng/mL; 
Sigma Aldrich, St. Louis, MO, USA) and ionomycin (1 µg/mL; 
Sigma Aldrich) and treated as described earlier.
Subsequently, a surface staining was performed to identify 
naive (CD45RO−CCR7+) and memory T  cell subsets (12). 
CM T  cells are CD45RO+CCR7+, effector memory (EM) 
CD45RO+CCR7−, and terminally differentiated effector memory 
(EMRA) CD45RO−CCR7−. In addition, less and more differenti-
ated T  cell subsets were also identified by CD28 (i.e., less dif-
ferentiated being CD28+ and more differentiated, lacking CD28, 
referred to as CD28null). The following monoclonal antibodies 
were used: brilliant violet (BV)-510-labeled anti-CD4 (Biolegend 
Europe BV, Uithoorn, The Netherlands), pacific blue-labeled 
anti-CD45RO (Biolegend), allophycocyanin-Cy7 (APC-Cy7)-
labeled anti-CD8 (BD, Erembodegem, Belgium), peridinin 
chlorophyll-Cy5.5 (PerCP-Cy5.5)-labeled anti-CD28 (BD), and 
phycoerythrin-Cy7 (PE)-Cy7-labeled anti-CCR7 (BD). Following 
fixation and permeabilization, cells were stained intracellular 
using APC-labeled anti-CD137 (BD) and PE-labeled anti-IFNγ 
(BD Pharmingen). IL-2-producing cells were only evaluated in 
a fraction of the patients tested, i.e., 12 CMV-seronegative and 
6 CMV-seropositive patients by co-staining intracellular using 
fluorescein isothiocyanate-labeled anti-IL-2 (BD). Samples were 
measured on the FACSCanto II (BD Pharmingen), aiming for 
0.5–1 × 106 of T cells to be acquired, and analyzed using FACSDiva 
software version 6.1.2 (BD). The gating strategy for identifying 
CMV-specific CD137+CD4+T  cells within the different subsets 
and in combination with cytokine production are shown in 
Figure S1 in Supplementary Material, a similar approach was 
followed for CD8+ T cells. The median (IQ range) background 
of CD137-expressing CD4+ T  cells of all samples amounted 
to 0.05% (0.03–0.07%) whereas that of CD137-expressing 
CD8+ T  cells was higher, amounting to 0.44% (0.23–1.02%). 
The median background value for CD137+IFNγ+CD4+ and CD8+ 
and CD137+IL-2+CD4+ T cells of all samples were 0.01% (0.01–
0.02%), 0.04% (0–0.09%), and 0.01% (0.01–0.01%), respectively. 
Most of the background signal within CD4+ T cells was observed 
in cells co-expressing CD28 and of a CM/EM phenotype whereas 
that observed for CD8+ T cells were predominantly lacking CD28 
and of the EM/EMRA phenotype. Since frequencies obtained for 
the various parameters differed considerably amongst patients, 
we subtracted the unstimulated value per patient from that after 
CMV-peptide stimulation to calculate the net signal as shown 
in the results. A positive detectable CMV-specific response was 
identified if the net response was over 0. Only detectable CD4+ 
and CD8+CD137+ CMV-specific T cell responses were analyzed 
in more detail with respect to cytokine production and pheno-
typic aspects.
Detection of cMV-specific Proliferating  
T cells
Peripheral mononuclear cells of 12 CMV-seronegative and 6 
CMV-seropositive patients were thawed and labeled with 
carboxyfluorescein diacetate succinimidyl ester according to 
the manufacturer’s instruction (CFSE; Molecular Probes®, 
The Netherlands) and subsequently stimulated in triplicate in 
standard culture medium at 5 × 104/well (96 wells-round bottom-
shaped plate) without or with CMV-lysate (30 µg/mL; Microbix 
Biosystems Inc., ON, Canada) or with a mixture of overlapping 
peptide pools covering the whole pp65 and IE-1 protein of CMV 
(both at a final concentration of 1 µg/mL; PepTivator-CMV pp65 
and IE-1; Miltenyi Biotec). Stimulation with CMV-lysate might 
allow for characterization of the total pool of CMV-specific 
CD4+ T  cells as the overlapping peptide pools cover only two 
(albeit dominant) peptides of the CMV protein. Proliferation of 
CMV-specific CD8+ T cells was only analyzed following stimula-
tion with overlapping peptide pools of pp65 and IE-1 and not 
whole CMV lysate due to their restriction with respect to length 
(number of amino acids) of the peptides presented in the context 
of HLA class I. Following 6  days, cells were harvested, stained 
using monoclonal antibodies directed against CD3, CD4, CD8, 
and CD28 (again to identify less differentiated versus more 
differentiated subsets amongst proliferating T  cells), and dead 
cells were excluded using 7-aminoactinomycin D. Samples were 
measured on the FACSCanto II (BD) and analyzed using FACS 
Diva software version 6.1.2 (BD), percentages of CMV-specific 
proliferating T cells were calculated by subtracting percentages 
of T cells proliferating in absence of these stimuli. The median 
(IQ range) of proliferating CD4+ and CD8+ T  cells in absence 
of a stimulus amounted to 0.83% (0.50–2.48%) and 1.42% 
(0.69–3.36%), respectively. A positive detectable response was 
identified if the net response was over 0.
Total and cMV-specific igg  
antibody-secreting cells (asc)
Peripheral mononuclear cells of 11 CMV-seronegative and, as a 
positive control, 4 CMV-seropositive patients were thawed and 
subsequently stimulated at a density of 2 ×  106/mL for 5  days 
with R848 and recombinant IL-2, according to the manufacturer’s 
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instruction (U-Cytech BV, Utrecht, The Netherlands). On day 4, 
the wells of a 96-well plate were coated overnight at 4°C according 
to the manufacturer’s instruction. Coating consisted of either an 
antihuman IgG antibody, for enumeration of total IgG ASC or 
CMV lysate (30 µg/mL Microbix Biosystems Inc., ON, Canada), 
for enumeration of CMV-specific IgG ASC. Following stimulation, 
cells were harvested, counted, and added to the coated ELISpot 
plate at different concentrations, each in triplicate. After a 7  h 
incubation (37°C, 5% CO2), cells were lysed and debris washed 
away using PBS/0.05% Tween-20. Subsequently, the wells of the 
ELISpot plate were incubated for 1 h at 37°C with a biotinylated 
antihuman IgG (detection) antibody and upon washing followed 
by an incubation with phi-labeled anti-biotin antibody (GABA) 
for 1  h at 37°C. Finally ASC were visualized, upon a washing 
procedure, using an activation solution (U-Cytech BV) resulting 
in a silver precipitate upon incubation in the dark at room tem-
perature. Color development was stopped using di-ionized water 
and spots were counted using an ELISpot reader (Bioreader®-
600V, BIO-SYS GmbH, Karben, Germany). CMV-IgG ASC are 
expressed as number/105 cells and a frequency of total IgG ASC.
In addition to analyzing ASC, a sample before and follow-
ing stimulation was analyzed for B cell blast formation by flow 
cytometry. The following panel of monoclonal antibodies was 
used: BV510-labeled anti-CD19 (Biolegend), BV421-labeled 
anti-CD38 (BD), and PE-Cy7-labeled anti-CD27 (eBioscience). 
Plasma blasts were CD19+CD38highCD27+.
absolute numbers of cD4+ and cD8+  
T cells and T-cell Differentiation status  
by Flow cytometry
Absolute numbers of T-cell subsets (18) and T-cell differentia-
tion status (19) were determined using a whole-blood staining 
as described in detail before.
Telomere length assay
Relative telomere length of CD4+ and CD8+ T cells were deter-
mined by Flow fluorescent in situ hybridization (flow-FISH) as 
described previously (15, 20).
statistical analyses
Statistical analyses were performed using GraphPad Prism 
version 5.01. Non-parametric Mann–Whitney U-test or Kruskal– 
Wallis test followed by a post  hoc analysis (Dunns multiple 
comparison test). Categorical variables were compared using the 
Fisher’s exact test. The non-parametric Spearman rank correlation 
coefficient (Spearman’s rho, Rs) was used to evaluate associations 
between various parameters. P-values <0.05 for two sides were 
considered statistically significant.
resUlTs
study Population characteristics
The demographic and clinical characteristics of the study popula-
tion are given in Table 1. Twenty-eight CMV-seronegative and 
14 age- and gender-matched CMV-seropositive patients were 
included in this study. Both groups were well matched with no sig-
nificant differences in clinical characteristics. Approximately half 
of the CMV-seronegative versus none of the CMV-seropositive 
patients experienced a CMV viremia within 12  months after 
transplantation (P < 0.01).
cMV-seronegative Patients Frequently 
have cMV-specific T cells
Cytomegalovirus-specific CD4+ and CD8+ T cells, identified by 
expression of CD137 upon stimulation with a peptide pool of the 
two immunodominant proteins pp65 and IE-1 (CD137+CD4+ and 
CD137+CD8+) were present in 16 out of 28 CMV-seronegative 
patients. Median (IQ range) values of the positive responses 
amounted to 0.03% (0.01–0.11%) and 0.10% (0.03–0.18%) for 
CD4+ and CD8+ T cells, respectively (Figures 1A,C, black dots). 
A positive correlation was observed between the CD4+ and CD8+ 
level of CMV-specific T-cell response in CMV-seronegative 
patients (Rs = 0.50, P < 0.05). The percentages of CMV-specific 
CD137-positive CD4+ and CD8+ T cells (present in 14 and 11 out 
of 14 CMV-seropositive patients, respectively) were significantly 
(P < 0.001) higher in CMV-seropositive patients and amounted 
to 0.61% (0.11–1.04%) and 1.45% (0.44–8.69%) (Figures 1A,C, 
open dots), respectively.
Cytomegalovirus-specific CD137+CD4+ and CD137+CD8+ 
T  cells were predominantly of the memory phenotype in both 
CMV-seropositive as well as CMV-seronegative patients. However, 
significantly higher percentages (P  <  0.05) of CD137+CD4+ 
and CD137+CD8+ T  cells in CMV-seronegative patients had a 
naive phenotype when compared to CMV-seropositive patients 
(Figures 1B,D, respectively). No differences were observed when 
comparing the maximal capacity of T  cells to express CD137 
between CMV-seronegative and CMV-seropositive patients upon 
PMA/ionomycin stimulation (Figures S2A,B in Supplementary 
Material).
cMV-specific T cells in cMV-seronegative 
Patients Produce iFnγ and il-2
Next, the presence and distribution of IFNγ- and IL-2-producing 
CMV-specific T  cells were studied. In 13 out of 28 CMV-
seronegative patients, CMV-specific IFNγ+CD137+CD4+T  cells 
were present and median (IQ range) frequencies amounted to 0.01% 
(0.01–0.04%) versus 0.58% (0.16–0.87%) for CMV-seropositive 
patients, that all had CMV-specific IFNγ+CD137+CD4+T  cells 
(Figure 1E, P < 0.001). In CMV-seronegative patients, approxi-
mately 37% of the CMV-specific CD137-expressing CD4+T cells 
produced IFNγ compared to 69% in CMV-seropositive patients 
(P < 0.05). IFNγ-producing CMV-specific CD137+CD4+ T cells 
all co-expressed CD28, and similar frequencies were present 
within the CM and EM subset of CMV-seronegative patients. In 
CMV-seropositive patients, a slightly more differentiated pheno-
type was observed as 16% (P < 0.01) of these cells lacked CD28 
and 75% were classified as EM T cells (Figure 1F).
In 12 CMV-seronegative and 6 CMV-seropositive patients, 
frequencies of IL-2-producing CD4+ T  cells specific for CMV 
were evaluated as we have previously shown these to be associated 
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FigUre 1 | Continued
with anti-CMV IgG titers (6). CMV-specific CD137+CD4+IL-2+ 
T cells were detected in 9 out of 12 (75%) of CMV-seronegative 
versus all of the CMV-seropositive patients and median (IQ 
range) frequencies amounted to 0.01% (0.01–0.01%) and 0.26% 
(0.01–0.87%) for CMV-seronegative and CMV-seropositive 
patients (P <  0.05; Figure 1G). Forty percent of CMV-specific 
CD137-expressing CD4+ T  cells of CMV-seronegative patients 
produced IL-2 compared to 37% in CMV-seropositive patients. 
In CMV-seronegative patients almost all IL-2-producing cells 
co-expressed CD28, in contrast to the presence of CD28null CMV-
specific IL-2-producing cells (10%) in the CMV-seropositive 
group (P < 0.01; Figure 1H).
IFN-γ-producing CD137+CD8+ T  cells were detected in 
11 out of 28 (39%) CMV-seronegative and 11 out of 14 (79%) 
CMV-seropositive patients. Median (IQ range) frequencies 
amounted to 0.05% (0.01–0.12%) and 0.64% (0.22–1.90%) within 
FigUre 1 | Cytomegalovirus (CMV)-specific CD137-expressing and cytokine-producing T cells. Peripheral mononuclear cells of patients were stimulated for 12-h in 
presence of brefeldin A and αCD49d alone or with a mixture of ppp65 and IE-1 overlapping peptide pools. Subsequently, cells are cell surface and intracellular 
stained to determine frequencies and phenotypic characteristics of CMV-specific CD137-expressing T cells as well as those producing cytokines. CMV-specific 
CD137-expressing CD4+ (a) and CD8+ (c) T cells, corrected for background (αCD49d only), are depicted as a percentage of total CD4+ or CD8+ T cells and the 
uncorrected values are set to 100% and dissected for CD4+ (B) or CD8+ (D) T cells co-expressing or lacking CD28 and the different naive and memory T cell 
subsets. A similar approach is followed for CMV-specific CD137-expressing IFN-γ and IL-2-producing CD4+ [(e,g) and dissection in (F,h)] and CD8+ [(i) and 
dissection in panel (J)] T cells, respectively. Closed and open symbols/bars represent CMV-seronegative (with a detectable response) and CMV-seropositive 
patients, respectively, and bars depict medians and interquartile range of the patient groups. *P < 0.05; **P < 0.01, ***P < 0.001.
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the total CD8+ T  cell population for CMV-seronegative and 
CMV-seropositive patients, respectively (Figure  1I, P <  0.01). 
Only 9% of CD137-expressing CD8+ T cells produced IFNγ in 
CMV-seronegative versus 36% of CMV-seropositive patients 
(P <  0.01). The differentiation status of these cells was similar 
for both groups and most IFNγ+CD137+CD8+ T  cells were 
found within the EM and highly differentiated EMRA subsets 
(Figure 1J). In CMV-seronegative patients, 65% of CMV-specific 
IFNγ-producing cells co-expressed CD28, in contrast to the pres-
ence of 89% CD28nullIFNγ-producing cells in CMV-seropositive 
patients (P <  0.05; Figure  1J). The frequency of CMV-specific 
CD137+CD8+ T cells producing IL-2 was low, i.e., median and 
IQ range amounted to: 0.001% (0.001–0.001%) and 0.024% 
(0.01–0.05%) of the total CD8+ T  cells for CMV-seronegative 
and CMV-seropositive patients, respectively. As less than 5% of 
CD137-expressing CD8+ T cells produced IL-2, no further dis-
section into T-cell subsets was done.
The CMV-specific CD137+CD4+ and CD8+ T cells with a naive 
phenotype, present at higher frequencies in CMV-seronegative 
patients (Figures  1B,D) did not produce IL-2 (Figure  1H) or 
IFNγ (Figures 1F,J).
Collectively, these data show that in a substantial fraction of 
CMV-seronegative patients cytokine-producing cells are present 
within CMV-specific CD137-expressing T cells, although at lower 
frequencies. Similar to CMV-seropositive patients, these are 
mainly of the memory phenotype albeit less differentiated as they 
7Litjens et al. CMV-Specific Immunity in CMVneg Patients
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1137
are more CD28+. No differences were observed when comparing 
the maximal capacity of T cells to express CD137 (Figures S2A,B in 
Supplementary Material) and produce cytokines between CMV-
seronegative and CMV-seropositive patients (Figures S2C–E in 
Supplementary Material).
cMV-specific T cell Proliferation in  
cMV-seronegative Patients
In addition to measuring the capacity to exert effector func-
tion by producing cytokines, we evaluated CMV-specific T cell 
proliferation by using both CMV-lysate and the peptide pool of the 
immunodominant proteins pp65 and IE-1 (Figures 2A,B, typical 
flowcytometric example). CMV-lysate-induced proliferation was 
observed in 10 out of 12 CMV-seronegative KT-recipients for 
CD4+ T  cells, respectively. Median (IQ range) percentages of 
proliferating CD4+ T  cells amounted to 2.2.55% (0.88–7.09%) 
(Figure  2C). Proliferation in response to the mixture of pp65- 
and IE-1-overlapping peptide pools was observed in a smaller 
proportion of CMV-seronegative patients, i.e., 7 and 3 out of 12 
KT recipients for CD4+ and CD8+ T cells [median and IQ range: 
0.35 and 0.09–0.64% (Figure  2C) and 0.33 and 0.19–1.00% 
FigUre 2 | Continued
FigUre 2 | Continued  
Cytomegalovirus (CMV)-specific T-cell proliferation. A typical example of the gating strategy for analysis of CMV-specific T cell proliferation is shown. Briefly, based 
on forward/sideward characteristics live cells are gated and depicted in a dot plot to further select living (7AAD-negative) CD3+ T cells (a). These were then further 
dissected into CD4+ and CD8+ T cells (a). CD4+ and CD8+ T cells are finally plotted to visualize proliferation (CFSE dilution) and CD28 expression and a typical 
example for background proliferation within CD4+ and CD8+ T cells is shown in the last two plots in panel A. In panel (B), typical (detectable) proliferative responses 
of CD4+ and CD8+ T cells to CMV-lysate (CD4+ T cells alone; upper graphs) or a mixture of overlapping peptides for pp65/IE-1 (both CD4+ and CD8+ T cells;  
middle and lower graphs, respectively) are depicted for a CMV-seronegative (left panel) and CMV-seropositive patient (right panel). Percentages of CMV-specific 
proliferating CD4+ and CD8+ T cells, corrected for frequencies of proliferating CD4+ or CD8+ T cells in absence of a stimulus, are depicted in panels  
(c,e), respectively. A dissection of uncorrected CMV lysate- or peptide-induced proliferating T cells (set to 100%) into those lacking or expressing CD28 are shown 
in panels (D,F) for CD4+ and CD8+ T cells, respectively. CMV-seronegative (with a detectable response) and CMV-seropositive patients are shown in closed and 
open symbols, respectively, and bars represent medians and interquartile range of the patient groups. *P < 0.05; **P < 0.01.
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(Figure  2E), respectively]. CD4+ T  cells of CMV-seropositive 
patients proliferated vigorously to CMV-lysate. The median 
percentage of proliferating CD4+ T cells was 36% (Figure 2C). 
Proliferation in response to the mixture of pp65- and IE-1-
overlapping peptide pools amounted to 6.34% (3.47–24.32%) 
and 9.64% (4.26–43.63%) for CD4+ and CD8+ T cells, respectively 
(Figures 2C,E). In CMV-seronegative patients, most (>97%) of 
the proliferating CD4+ T cells co-expressed CD28, indicative for 
a less differentiated phenotype. In CMV-seropositive patients 
approximately 10% of all proliferating CD4+ T cells were CD28null 
(Figure  2D). This difference in differentiation status was even 
more pronounced in proliferating CD8+ T cells as 78% of these 
cells in CMV-seronegative patients expressed CD28 compared 
to approximately 34% of CMV-seropositive patients (P < 0.05) 
(Figure  2F). Frequencies of CMV-specific IFNγ-producing 
CD137+CD4+ T cells and IL-2-producing CD137+CD4+ T cells 
were positively correlated with percentages of proliferating CD4+ 
T cells [for IFNγ: Rs = 0.63; P = 0.02 (CMV-lysate) and Rs = 0.71; 
P =  0.02 (pp65/IE-1 peptides), for IL-2: Rs =  0.62; P =  0.02 
(CMV-lysate) and Rs = 0.74; P = 0.01 (pp65/IE-1 peptides)].
low Frequency of cMV-specific igg  
asc in cMV-seronegative Patients
Next we evaluated whether CMV-specific memory B cells could 
be detected in the circulation of CMV-seronegative patients. The 
frequency of plasma blasts within the circulation is very low but 
can be induced from B  cells upon polyclonal stimulation. The 
total B cell number and responses may be negatively affected in 
ESRD patients and therefore we first documented that this pro-
tocol can indeed induce plasma blasts. As shown in Figure 3A, 
plasma blasts were induced (CD27+CD38highCD19+, from 1.4 to 
48.1%) following a 5-day polyclonal stimulation. Next, total IgG 
and CMV-IgG ASC were quantified by ELISpot. CMV-IgG ASC 
were detected above background in 4 out of 11 (36%) of CMV-
seronegative patients and net median (IQ range) CMV-specific 
IgG ASC amounted to only 1/105 (1–10/105), i.e., 0.08% (0.02–
0.14%) of total IgG ASC (Figures 3B,C). All CMV-seropositive 
patients had detectable CMV-IgG ASC [median 45 cells/105 
(7–114/105), 0.38% (0.11–1.70%) of total IgG ASC]. Interestingly, 
CMV-specific IFNγ- as well as IL-2-producing CD137+CD4+ 
T cells of the total patient group (CMV-seropositive and CMV-
seronegative patients) were positively correlated with numbers 
of CMV-specific IgG ASC (Rs = 0.52; P < 0.05 and Rs = 0.53; 
P < 0.05, respectively).
cMV-specific cD137+iFnγ+cD4+ T cell 
responses Protect against cMV Viremia
The CMV-specific T-cell response in CMV-seronegative patients 
was evaluated for clinical relevance by relating it to the occur-
rence of CMV viremia after transplantation. In 13 out of 28 (46%) 
CMV-seronegative patients, a CMV viremia developed during 
the first year following transplantation with a CMV-seropositive 
donor kidney. CMV-seronegative patients with CMV-specific 
CD137+IFNγ+CD4+ T  cells before transplantation had a lower 
risk to develop a CMV viremia after transplantation with a CMV-
seropositive donor kidney compared to those without (relative 
risk: 0.43, P =  0.03). No differences in percentages of CMV-
specific IFNγ-producing CD137+CD4+ T  cells were observed 
between CMV-seronegative patients without and those with a 
CMV viremia (data not shown).
cMV-associated T-cell Defects  
Mimicking T-cell aging are not Present  
in cMV-seronegative Patients with  
cMV-specific T cells
Cytomegalovirus latency leaves a clear fingerprint on the T cell 
immune system. The CMV-associated changes in the circulat-
ing T  cell compartment of CMV-seropositive ESRD patients 
comprise of a reduced telomere length, significant expansion of 
the CD8+ T cell pool and increased differentiation status of the 
memory T cells, notably the induction of CD28null T cells in both 
CD4+ and CD8+ T  cells (21, 22). However, such changes were 
not observed when comparing CMV-seronegative patients with 
and without detectable CMV-specific CD137-expressing IFNγ-
producing CD4+ T cells (Table 2).
DiscUssiOn
In this study, we evaluated the presence of CMV-specific cellular 
and humoral immunity in a cohort of CMV-seronegative patients 
and assessed the clinical relevance with respect to the risk for 
a CMV viremia after kidney transplantation. Data revealed the 
presence of a low frequency of CMV-specific T-cells in over half 
of these patients. Interestingly, in particular IFNγ-producing 
CMV-specific CD4+ T cells were associated with protection from 
CMV viremia following transplantation with a kidney from 
a CMV-seropositive donor. Thus, a protective anti-CMV cellular 
immunity may exist in the absence of serum anti-CMV IgG.
TaBle 2 | Effects of CMV-immunity on T-cell parameters before transplantation.
cMVpos esrD  
patients (N = 14)
cMVneg esrD patients without cMV-specific 
cD137+iFnγ+cD4+ T cells (N = 15)
cMVneg esrD patients with cMV-specific 
cD137+iFnγ+cD4+ T cells (N = 13)
P-value*
T cells 1,184 (887–1,519) 1,039 (636–1,360) 1,057 (750–1,340) ns
CD4+ T cells 629 (444–786) 714 (373–916) 639 (451–821) ns
CD4+ Tnaive cells 110 (73–173) 213 (119–531) 226 (163–354) ns
CD4+ TMEM cells 535 (292–641) 385 (185–512) 434 (255–641) ns
CD4+ TCM cells 263 (174–389) 227 (137–366) 283 (176–363) ns
CD4+ TEM cells 185 (106–301) 116 (100–148) 108 (80–273) ns
CD4+ TEMRA cells 7 (5–21) 11 (4–18) 8 (3–13) ns
CD4+CD28null T cells 29 (3–65) 3 (2–5) 3 (1–20) ns
CD4+CD31+ Tnaive cells 63 (43–123) 170 (61–264) 144 (91–222) ns
CD8+ T cells 465 (316–618) 257 (168–445) 240 (213–469) ns
CD8+ Tnaive cells 84 (39–120) 104 (59–198) 84 (44–179) ns
CD8+ TMEM cells 349 (271–528) 140 (87–277) 191 (167–246) ns
CD8+ TCM cells 15 (9–88) 16 (7–30) 25 (13–44) ns
CD8+ TEM cells 110 (59–144) 85 (46–188) 83 (53–122) ns
CD8+ TEMRA cells 151 (85–287) 37 (25–69) 41 (18–76) ns
CD8+CD28null T cells 228 (85–276) 37 (24–86) 58 (23–67) ns
CD8+CD31+ Tnaive cells 79 (39–118) 98 (57–175) 76 (41–175) ns
CD4+ RTL 10.20 (9.2–15.2) 11.2 (9.1–17.8) 12.1 (9.4–14.1) ns
CD8+ RTL 10.85 (7.7–14) 13 (9.7–21.2) 11.4 (9.1–16) ns
Cell numbers are given in cells/μL blood; data represent median (interquartile range).
*When comparing CMVneg ESRD patients without to those with CMV-specific CD137+IFNγ+CD4+ T cells.
MEM, memory; CM, central memory; EM, effector memory; EMRA, terminally differentiated effector memory (CD45RA+);  
RTL, relative telomere length given as a %; ESRD, end-stage renal disease.
FigUre 3 | Cytomegalovirus (CMV)-specific B-cell responses. A B cell ELISpot assay was performed to enumerate CMV-specific and total immunoglobulin G (IgG) 
antibody-secreting cells (ASC). In panel (a), a typical flow cytometric example is given of B cell blasts, identified as CD19+CD27+CD38high cells, before a following a 
5-day stimulation with R848 and recombinant IL-2 on the left side. On the right side, the individual and median frequencies of B cell blasts are depicted before 
stimulation and following a 5-day stimulation for 15 kidney transplant recipients (11 CMV-seronegative and 4 CMV-seropositive patients). Following B-cell 
stimulation, cells were transferred at different numbers/well to wells of a 96-well B-ELISpot plate coated with CMV-lysate or an antihuman IgG antibody or not 
coated (containing PBS; background IgG-producing cells). In panel (B), representative examples are shown for background, CMV-specific and total IgG ASC as 
determined within CMV-seropositive and CMV-seronegative patients. In panel (c), individual and median (detectable) CMV-specific and total IgG ASC, corrected for 
background (number of spots in absence of a coating antibody) for CMV-seropositive (open symbols) and CMV-seronegative (closed symbols) patients are depicted. 
*P < 0.05; ***P < 0.001.
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Presence of cellular immunity in the absence of protective 
antibodies is not uncommon. Possible explanations for this 
disassociation may be that either cellular immunity is inef-
ficient to induce adequate humoral immunity (6, 7) or that 
protective antibodies are not adequately maintained. Both these 
mechanisms may hold true for patients with ESRD. It is known 
that T-cell dependent vaccines (e.g., HBsAg, tetanus toxoid, 
and diphtheria) are poor inducers of protective antibody titers 
in these patients, and antibody titers are poorly maintained 
(23–25). A detailed analysis of the dynamics and quality of the 
antigen-specific T  cell response after vaccination with HBsAg 
in ESRD patients showed a poor generation of memory CD4+ 
T  cells (6, 7). In particular, the presence of antigen-specific 
CD4+ EM T cells correlated significantly with the titers of anti-
HBsAg and a similar relation could be shown for anti-CMV IgG. 
The results of this study also showed a statistically significant 
relation between the presence of IL-2 or IFNγ-producing CMV-
specific CD4+ T  cells and anti-CMV IgG ASC. Therefore, a 
weak induction of a CMV-specific T cell response may underlie 
the inadequate generation of an anti-CMV humoral response. 
In addition, it could still be possible that a low but detectable 
anti-CMV humoral response was generated initially but not 
adequately maintained.
Although there may be concerns associated with reliably 
measuring low frequencies of CMV-specific T cells, the multi-
parameter CD137 flow cytometric assay as described previously 
(17), allows for a detailed characterization of total pool of antigen-
specific T cells which is related with other parameters analyzed 
within this paper and is associated with clinical outcome, i.e., 
CMV viremia. The detailed analysis of the CMV-specific response 
within T cell subsets revealed that CMV-specific memory CD4+ 
and CD8+ T cells were less differentiated in the CMV-seronegative 
patients than in CMV-positive patients. This was evident by 
relatively more CD28+ memory T  cells and less CMV-specific 
T cells producing effector cytokines such as IFNγ and IL-2. Of 
interest was the detection of a CMV-specific CD137+ response 
in phenotypically naive T cells that did not produce cytokines. 
These cells may be part of so-called early branched off memory 
T cells that are phenotypically naive T cells but are in fact memory 
T cells in an early developmental stage of which some are able to 
exert effector function (26). Again this finding supports the con-
cept of a less well-differentiated CMV-specific T-cell response. 
In this respect, a paper by Redeker et al. (27) nicely illustrated, 
in a mouse model, the large inter-individual variations in the 
height of the CMV-specific T cell responses to be dependent on 
the initial viral load which also influences the extent of memory 
T-cell inflation and phenotype of CMV-specific T  cells. CMV 
infection generally leads to long-lasting substantial changes in 
circulating T cells, even more so in ESRD patients (13, 28–31). 
In particular, highly differentiated EMRA T cells lacking CD28 
T cells are expanded in the CD8+ T cell population and to a lesser 
extent in the CD4+ T cell population (13–15). This typical foot-
print of CMV infection in the composition of circulating T cells 
was not found in the CMV-specific T cells of CMV-seronegative 
patients. This indicates that these patients have encountered 
CMV but only mounted a limited T cell response. The most likely 
explanation is low-level of exposure to viral antigens that may not 
result in the specific imprint induced by high viral antigen expo-
sure which results in sustained CMV-specific IgG serum titers 
(32, 33). Furthermore, a proportion of CMV-seropositive patients, 
had no or low frequencies of CMV-specific CD8+ T cells but had 
CMV-specific CD4+ T cells as well as CMV-IgG-producing cells 
before transplantation, that were sufficient to prevent from a 
CMV reactivation. This was in contrast with a paper by Tey et al. 
that described hematopoietic stem cell transplant recipients, a 
different group of immunocompromised patients, deficient in 
reconstituting CMV-specific immunity to have higher viral loads 
(34). Our data are remarkably consistent with a recent study by 
Lucia et al. (11) that identified CMV-specific T cell responses in 
30% of CMV seronegative individuals. However, their data were 
generated by ELISpot and therefore lack a more in-depth analysis 
of the T cell subsets involved. They also claim the detection of 
CMV-specific memory B cells but frequencies were unfortunately 
not reported.
In conclusion, assessment of anti-CMV-IgG does not seem 
to suffice for properly identifying CMV-naive individuals, as a 
significant proportion has a weak cellular CMV-specific response, 
which is associated with protection against CMV viremia after 
transplantation with a CMV-seropositive donor kidney. We 
therefore propose to include assessment of cellular immunity in 
the risk assessment before kidney transplantation. Furthermore, 
monitoring of CMV-specific cellular immunity following trans-
plantation, i.e., at the end of anti-CMV prophylaxis might be 
useful for further identifying patients at risk for a CMV viremia, 
requiring additional antiviral therapy or adjustment of immuno-
suppressive medication (35).
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FigUre s1 | Typical gating strategy for cytomegalovirus (CMV)-specific 
CD137-expressing and cytokine-producing CD4+ T cells. A typical flow-
cytometric example is depicted for analysis of CMV-specific CD137-expressing 
and cytokine-producing CD4+ T cells for a CMV-seropositive (a–c) and 
CMV-seronegative (D–F) patient. Briefly, based on forward/sideward 
characteristics, live cells are gated and depicted in a dot plot to further select 
CD4+ and CD8+ T cells. The CMV-specific CD137-expressing CD4+ T cells are 
selected [(a,D), first plot] as well as the IFNγ and IL-2 cells within CD137-
expressing CD4+ T cells [(a,D), second plot]. CD137-expressing CD4+ T cells  
are subsequently dissected into naive and different memory T cell subsets  
[(a,D), third plot] using CCR7 and CD45RO expression [CCR7+CD45RO−: naive, 
CCR7+CD45RO+: central memory (CM), CCR7−CD45RO+: effector memory (EM) 
and CCR7−CD45RO−: EMRA] or CD28+ and CD28null T cells [(a,D), fourth plot]. 
IFNγ (B,e) and IL-2 (c,F)-producing CD137-expressing CD4+ T cells were 
analyzed in a similar way. Furthermore, the same approach was also applied for 
analysis of CMV-specific CD137-expressing and cytokine-producing CD8+ T cells 
(not shown). Percentages of CD137-expressing CD4+ T cells are of total CD4+ 
T cells and percentages of cytokine+ within CD137+CD4+ T cells are given as a 
proportion of CD137+CD4+ T cells (set to 100%) and in brackets the frequency of 
CD137+cytokine+ within total CD4+ T cells is depicted. The dissection with 
respect to a certain T-cell phenotype is done by setting the% of CD137+ or 
CD137+cytokine+CD4+ T cells to 100%.
FigUre s2 | CD137-expressing and cytokine-producing T cells upon 
stimulation with phorbol myristate acetate (PMA) and ionomycin. Peripheral 
mononuclear cells of patients were stimulated for 12-h in presence of 
brefeldin A and αCD49d alone or with a mixture of PMA and ionomycin. 
Subsequently, cells are cell surface and intracellular stained to determine  
the maximal capacity of T cells to express CD137 and produce cytokines. 
PMA/ionomycin-induced CD137-expressing CD4+ (a) and CD8+ (B) T cells, 
corrected for background (αCD49d only), are depicted as a percentage of 
total CD4+ or CD8+ T cells. A similar approach is followed for PMA/
ionomycin-induced CD137-expressing IFN-γ- and IL-2-producing CD4+ 
(c,e) and CD137-expressing IFN-γCD8+ T cells (D). Closed and open 
symbols/bars represent cytomegalovirus (CMV)-seronegative and CMV-
seropositive patients, respectively.
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